Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2022-09-19 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于股东权益变动提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about changes in significant shareholdings of a company, including percentages of shares held by major shareholders before and after the changes, explanations of stock incentive plans, share repurchases, and regulatory compliance references. It specifically discusses shareholding changes exceeding 5%, which is typical for major shareholding notifications. There is no indication that this is a full financial report, earnings release, or management discussion. The document length is under 5,000 characters and it contains detailed shareholding data rather than just a brief announcement or a certification. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2022-09-19 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding percentages and numbers for specific shareholders (宋勇, 易湘苹, 宋洁) in the company 迪瑞医疗科技股份有限公司. The document includes detailed disclosures about shareholding changes, reasons for changes, legal compliance, and declarations by the shareholders. It references relevant Chinese securities laws and regulations governing equity changes and disclosures. The content is focused on reporting changes in major shareholdings and related disclosures rather than financial performance, management changes, or other corporate events. The document length is substantial (over 13,000 characters), and it contains detailed data and explanations about shareholding changes. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Therefore, the appropriate classification is MRQ with high confidence.
2022-09-19 Chinese
关于2022年限制性股票激励计划授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the registration of a 2022 restricted stock incentive plan by the company. It details the number of shares granted, the recipients, the grant price, the source of shares (repurchased shares), approval procedures, performance conditions, and other related information. It is not a financial report, earnings release, or management discussion, but rather a formal announcement about a capital incentive plan and related share registration. This fits best under the category of Capital/Financing Update (CAP), as it relates to share-based compensation and capital structure changes due to stock incentives.
2022-09-19 Chinese
2022-082 迪瑞医疗：关于持股5%以上股东及一致行动人减持股份预披露公告
Director's Dealing Classification · 95% confidence The document is a public announcement regarding a planned reduction in shareholding by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number and percentage of shares to be reduced, the methods and timing of the reduction, and legal compliance assurances. There are no financial statements, earnings data, or management discussions. The document is a notification of insider share transactions by major shareholders, specifically about their intention to sell shares. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives. The document length is under 5,000 characters and is a standalone announcement, not a report or regulatory filing. Therefore, the correct classification is DIRS with high confidence.
2022-09-07 Chinese
关于参股公司首次公开发行股票申请获深圳证券交易所创业板上市委员会审议通过的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (545 characters) about a shareholder company (Xiamen Zhishan Biotechnology Co., Ltd.) passing the review for its initial public offering on the Shenzhen Stock Exchange. It includes details about the shareholding percentage and mentions ongoing regulatory procedures. There is no financial data, no detailed report, and the document is primarily an update on a capital market event related to share issuance and listing approval. It is not a full report but an announcement of a financing-related event. Therefore, the best fitting category is Capital/Financing Update (CAP).
2022-09-06 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于迪瑞医疗2022年限制性股票激励计划授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2022 restricted stock incentive plan of a company. It contains detailed information about the stock incentive plan, including definitions, approval procedures, grant details, conditions, and the advisor's verification opinions. The content is focused on the stock incentive plan and its approval, which is a specialized financial advisory report rather than a general annual or quarterly financial report. It is not a simple announcement or a brief summary but a detailed advisory report. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone advisory report related to financial and regulatory compliance matters concerning stock incentives, not a full annual report or earnings release. FY 2022
2022-08-29 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.